Simplify Asset Management Inc. Acquires Shares of 11,237 TG Therapeutics, Inc. (NASDAQ:TGTX)

Simplify Asset Management Inc. bought a new position in TG Therapeutics, Inc. (NASDAQ:TGTX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 11,237 shares of the biopharmaceutical company’s stock, valued at approximately $338,000.

Other large investors have also recently made changes to their positions in the company. Victory Capital Management Inc. lifted its stake in TG Therapeutics by 24.7% in the third quarter. Victory Capital Management Inc. now owns 32,679 shares of the biopharmaceutical company’s stock worth $764,000 after purchasing an additional 6,467 shares during the last quarter. Empowered Funds LLC raised its holdings in shares of TG Therapeutics by 3.1% in the third quarter. Empowered Funds LLC now owns 46,431 shares of the biopharmaceutical company’s stock worth $1,086,000 after buying an additional 1,386 shares during the period. Mutual of America Capital Management LLC bought a new stake in shares of TG Therapeutics during the 3rd quarter worth approximately $469,000. Thrivent Financial for Lutherans purchased a new position in TG Therapeutics during the 3rd quarter valued at $2,450,000. Finally, Quest Partners LLC bought a new position in TG Therapeutics in the 3rd quarter valued at $246,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

TG Therapeutics Price Performance

Shares of TGTX opened at $42.99 on Friday. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a 50 day moving average price of $33.17 and a 200-day moving average price of $29.68. TG Therapeutics, Inc. has a fifty-two week low of $12.93 and a fifty-two week high of $43.15. The stock has a market capitalization of $6.75 billion, a PE ratio of -429.86 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company had revenue of $108.19 million during the quarter, compared to analyst estimates of $100.67 million. Equities analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. JPMorgan Chase & Co. upped their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 4th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, TG Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $40.67.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at approximately $18,847,231.83. The trade was a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 10.50% of the stock is owned by corporate insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.